Cite
HARVARD Citation
Cristescu, R. et al. (2022). Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. Journal for immunotherapy of cancer. 10 (1), p. . [Online].